Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Abbott reinforces will...

    Abbott reinforces will to fight odds and retain Indian Market

    Written by Geeta Sharma Sharma Published On 2016-03-20T10:25:30+05:30  |  Updated On 20 March 2016 10:25 AM IST
    Abbott reinforces will to fight odds and retain Indian Market





    Abbott has voiced determination to stay in the healthcare business despite bans imposed on its products. Abbott had in 2015 revealed that it has invested over Rs 25,600 crore in India over the last five years. India is the third largest market for Abbott, behind the US and China, contributing just over $1 billion in sales.

    Abbott had moved the high court Tuesday last is now reiterating its determination to become an active participant in the Prime Minister, Mr. Modi's 'Make in India' programme. It is also planning to bring its top selling over- the- counter (OTC) nutrition brands to India. According to market analysts, Abbott currently produces almost 70% of its OTC and pharma products in India.

    “Our focus in India is to manufacture some of our key brands locally. We have also invested $75 million to set up a green-field manufacturing facility in India to increase local procurement,” Amal Kelshikar, country head, nutrition, Abbott India told HT.

    The company’s top OTC brands in nutrition category includes PediaSure, Similac, NeoSure and SimMom among others.

    Other pharma giants such as Sun Pharma and Glaxo SmithKline are finding, nutrition is among the fastest growing businesses in India.

    “Our nutrition business has grown well over the past three years, registering a consistent double-digit growth year-on-year. This growth has come at a time under conditions which led to some slowing down of the market,” said Kelshikar. He did not give absolute growth figures.

    In an attempt to localise product offerings, Abbott India has engaged its nutrition research centre in Bengaluru to work with its manufacturing plant in Gujarat . The centre focuses on product design, development and delivery specifically for the Indian consumer, with emphasis on local tastes and preferences as well as nutritional needs.

    IMS Health data records the organised nutrition market in India at Rs 6,433 crore in 2015. According to the health data factors such as increasing incidence of non-communicable diseases, high numbers of premature births, anaemia among pregnant women, toddlers trailing on developmental milestones etc have created a need for specific, clinically proven nutrition products.


    AbbottAmal KelshikarNeo SurenutraceuticalsNutritionPedia SureSimilacSimMom
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Geeta Sharma Sharma
    Geeta Sharma Sharma
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok